Clinical trials: Atomoxetine Hydrochloride
ADHD, Attention Deficit Hyperactivity Disorder
Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children and adolescents ages 6-17.
- Trial name
- NCT00585910
- Testing
- Atomoxetine and OROS Methylphenidate
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Disorder With Hyperactivity
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
This study will determine the effectiveness of stimulant and nonstimulant medication in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in children and adolescents.
- Trial name
- NCT00183391
- Testing
- Atomoxetine, Methylphenidate
- Where
- 2 sites in United States
- Volunteers
- 232 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, ADHD
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
The growing number of medications used to treat attention-deficit/hyperactivity disorder (ADHD) raises important questions about whether different medications have similar or different therapeutic mechanisms of action.
- Trial name
- NCT01678209
- Testing
- fMRI scans, Atomoxetine arm, Methylphenidate arm
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to provide information regarding the relative effectiveness of three different atomoxetine doses in the treatment of Korean children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00568685
- Testing
- Atomoxetine Hydrochloride
- Where
- 3 sites in South Korea
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Alcohol Use Disorder
Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine
The primary objectives of this study are twofold. The first primary objective is to evaluate the feasibility, acceptability, and tolerability of atomoxetine (40 mg/day for 3 days then 80 mg/day thereafter) as compared to placebo…
- Trial name
- NCT04565288
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Brown University
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).
The study is a phase IIIb multicentre, randomised, placebo controlled, trial in paediatric patients with Attention-Deficit/Hyperactivity (ADHD) and Oppositional Defiant Disorder (ODD).
- Trial name
- NCT00192023
- Testing
- atomoxetine 0.5 mg/kg/day, atomoxetine 1.2 mg/kg/day, atomoxetine 1.2-1.4 mg/kg/day
- Where
- 12 sites in Italy
- Volunteers
- 139 people
- Sponsor
- Eli Lilly and Company
ADHD
Atomoxetine PBPK-PD Clinical Study
The primary aims of this study focus on characterizing the relationship between atomoxetine exposure and clinical outcomes, as assessed by standardized measures.
- Trial name
- NCT03154359
- Testing
- Atomoxetine Hydrochloride
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Children's Mercy Hospital Kansas City
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Obstructive Sleep Apnea, Down Syndrome
Medications for Obstructive Sleep Apnea In Children With Down Syndrome
This is a randomized, double blind, cross-over study of the combination of atomoxetine and oxybutynin (ato-oxy) in children with DS and OSA documented by polysomnography (PSG).
- Trial name
- MOSAIC (NCT04115878)
- Testing
- Atomoxetine and oxybutynin (ato-oxy)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arizona
Attention Deficit Hyperactivity Disorder
A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
The purpose of the study is to investigate the relationship of changes in measures of academic performance and problem behaviors, to changes in core Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in Asian children…
- Trial name
- NCT00471354
- Testing
- Atomoxetine
- Where
- 8 sites in China, South Korea and 1 more
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Substance Abuse
Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder
The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.
- Trial name
- NCT00399763
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Attention Deficit Hyperactivity Disorder
Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD
Background: Multiple studies have found Atomoxetine (Strattera) to be efficacious but there is only one published study specifically designed to evaluate its efficacy in school settings.
- Trial name
- NCT00918567
- Testing
- atomoxetine, Behavior Modification Therapy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- State University of New York at Buffalo
ADHD
Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication
The purpose of this study is to see if supplementing calories with Pediasure is effective in maintaining height, weight, and BMI percentiles for young children during 2 years of treatment with ADHD medication.
- Trial name
- NCT00561340
- Testing
- Pediasure, Nutritional counseling
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Nebraska
Attention Deficit Hyperactivity Disorder
Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)
The study is long-term extension study to evaluate long-term safety and efficacy of Atomoxetine in Japanese pediatric patients with Attention-Deficit/Hyperactivity Disorder (AD/HD).
- Trial name
- NCT00191386
- Testing
- Atomoxetine hydrochloride
- Where
- 24 sites in Japan
- Volunteers
- 228 people
- Sponsor
- Eli Lilly and Company
Autistic Disorder, Attention Deficit Disorder With Hyperactivity
Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in children and adolescents with ASD (Autism Spectrum Disorder).
- Trial name
- NCT00380692
- Testing
- Atomoxetine
- Where
- 8 sites in Netherlands
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Autism
Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
This study will evaluate the effectiveness of atomoxetine in treating children with attention deficit hyperactivity disorder symptoms associated with autistic disorder, Asperger's syndrome, and pervasive developmental disorder…
- Trial name
- NCT00498173
- Testing
- Atomoxetine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity…
- Trial name
- EMD (NCT01127646)
- Testing
- Atomoxetine, Osmotic-release oral system methylphenidate
- Where
- 14 sites in Netherlands, Spain and 1 more
- Volunteers
- 23 people
- Sponsor
- Eli Lilly and Company
Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
Determine if atomoxetine is safe and well tolerated by children with fetal alcohol syndrome.
- Trial name
- B4Z-US-050 (NCT00418262)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Oklahoma
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1).
- Trial name
- NCT00191945
- Testing
- Atomoxetine Hydrochloride
- Where
- 11 sites in Spain
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company